Incyte to Acquire Escient Pharmaceuticals and its MRGPR Antagonist Assets

Share this


Incyte to Acquire Escient Pharmaceuticals and its MRGPR Antagonist Assets


  • Incyte to acquire Escient Pharmaceuticals for $750 M plus Escient’s remaining net cash at closing of transaction (based on customary adjustments). Closing of acquisition is anticipated in Q3’24
  • Acquisition will enhance Incyte’s R&D activities in Inflammation and Autoimmunity (IAI) by addition of Escient's MRGPR antagonists, EP262 and EP547; possible launch begins in 2029
  • Moreover, EP262 in the P-I study showed safety and tolerability at all doses tested with no AEs & SAEs, vital signs, or ECG parameters, whereas TEAEs were mild having incidence lesser than PBO (33.3% vs. 62.5%) and did not rise with change in dose

Ref: Incyte | Image: Incyte

Related News:- Incyte and China Medical System Sign a Collaboration & License Agreement for Povorcitinib Use in Autoimmune and Inflammatory Dermatologic Indications

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions